Innovator Community Expansion Initiative (ICEI)
The Innovator Community Expansion Initiative (ICEI) seeks to increase the output of commercially actionable and patient centric innovation by growing and diversifying the innovator community at MGB. The program focuses on identifying and eliminating barriers to the innovation process for women, individuals who are underrepresented in medicine (URM), clinicians and emerging innovators. ICEI, a data-driven initiative, focuses on: providing education and resources related to the commercialization process, building connections within the system and with industry, and providing networking development opportunities for our diverse and distinguished faculty.
Innovation Fellows Program
The Innovation Fellows Program is a new initiative that seeks to increase collaboration between the Mass General Brigham community and industry. It is an opportunity for a personnel exchange between Mass General Brigham core hospitals – Brigham and Women’s Hospital, Massachusetts General Hospital, and McLean Hospital – and participating biopharmaceuticals, venture capital firms, and other commercial entities.
2023 Call for Brief Pre-Proposals: Deadline May 26, 2022
We are pleased to announce the eighth annual call for pre-proposals for the Sanofi iAwards Program, which aims to fund innovative and translational research ideas that can contribute to our early stage pipeline and ultimately benefit patients
The iAwards program provides $125,000 in research funding for a one-year study, and successful projects have the potential to grow into sponsored research agreements with significantly increased funding and timelines. Over the past 7 years, 26 projects have been funded at BWH and MGH across a diverse range of therapeutic areas.
Innovation Discovery Grants
The Innovation Discovery Grants (IDG) program aims to enhance the commercial outcomes of the Mass General Brigham community and to increase its innovative potential. It is designed to stimulate new inventive concepts, identify areas of commercially significant scientific strength, and accelerate commercialization of Mass General Brigham intellectual assets. The IDG program will fund projects that can demonstrate tangible outcomes towards commercialization licensing opportunities, or a spin-off company, based on a drug, device, diagnostic, healthcare IT, or other product or service that improves patient health or healthcare delivery.